GLP-1 Access Is EXPLODING… But Something Else Is Happening
If you just look at the headlines, things look great for access to GLP-1 medications but for some of those already using these medications things are changing and getting tighter. Listen in as Dave br...
7 Apr 23min
Zepbound Dosing: What Your Doctor Didn't Explain
Are you on tirzepatide or semaglutide and struggled with inconsistent weight loss and side effects? On this episode of On The Pen, Dave Knapp and Dr. Ian Ellis dive into the surprising variability of ...
2 Apr 1h 13min
Wegovy Price Drop Exposes a Bigger Problem
A major shift in obesity treatment is underway following a surprising pricing move that could change how patients access care. This episode explores the growing divide between traditional healthcare a...
31 Mars 18min
Retatrutide Is Too Good… And That’s The Problem
Access to compounded and research-grade GLP-1s may be tightening, as comments from Robert F. Kennedy Jr. signal increased enforcement and a push back toward branded medications. At the same time, new ...
24 Mars 29min
MASSIVE: Compound Tirzepatide and Semaglutide Updates!
On The Pen breaks down the latest GLP-1 news, compounded semaglutide updates, tirzepatide controversy, FDA and DDC list developments, Novo Nordisk findings, Eli Lilly B12 tirzepatide concerns, and new...
17 Mars 26min
Cheap Zepbound Incoming for Medicare, But CMS Just Issued a Catch
Send a textOn this episode of the podcast, host Dave Knapp breaks down the latest updates on potential GLP-1 receptor agonists coverage for people on Medicare living with obesity. With new guidance re...
10 Mars 20min
Gray Market GLP-1 Is Booming Branded Access is Broken
Send a textEpisode Summary (Short Version):This week on On The Pen, Dave breaks down the rapid changes reshaping GLP-1 access — from new federal reforms targeting PBMs and possible FDA limits on compo...
3 Mars 26min
UBT251 FROM NOVO NORDISK! BETTER THAN RETATRUTIDE?
Send a textThis episode unpacks Novo’s aggressive price cuts, Lilly’s head to head trial win, and the emerging triple agonist race, revealing how pricing strategy and next generation data are collidin...
24 Feb 27min
